Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06815354 · ClinicalTrials.gov registry record · NA
Comprehensive Assessment of Cancer Theranostic Response
A NA study of Prostate Cancer, sponsored by AIQ Solutions.
- Recruiting
- Registry status
- NA
- Development phase
- 32
- Enrollment target
- 2
- Study locations
NCT06815354: Recruiting NA study of Prostate Cancer, sponsored by AIQ Solutions.
NCT06815354 is a NA study of Prostate Cancer that is actively recruiting participants, run by AIQ Solutions. The registered enrollment target is 32 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06815354, a NA study of Prostate Cancer, is actively recruiting participants, sponsored by AIQ Solutions.
- RECRUITING
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
- 2
- Study locations
Study Summary
The intent of this study is to evaluate actionable outputs from TRAQinform Theranostics in a prospective, multi-center, non-interventional clinical study. The primary objective is to investigate intent-to-change treatment decisions after the addition of TRAQinform Theranostics. The exploratory objective is to investigate if treatment efficacy and treatment-related toxicity could be detected by TRAQinform Theranostics following PSMA PET/CT at week 12.
Primary Outcome
Medical teams make a treatment decision using the PSMA PET/CT, diagnostic CT, and other clinical data without the TRAQinform Theranostics analysis report. A treatment decision questionnaire is completed. The medical team is then given the TRAQinform Theranostic report, and the treatment decision questionnaire is completed again. TRAQinform Theranostic analyzes PSMA PET/CT and CTs. A pdf report allows a medical team to view and interpret the TRAQinform outputs. The report is a theranostic tracer
Conditions Studied
Interventions
- DEVICE TRAQinform Theranostics
Study Locations (2)
New York
- Weill Medical College of Cornell - New York
Texas
- M.D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2024-12-02 |
| Est. Completion | 2026-05-29 |
| Phase | NA |
What NCT06815354 shows while recruiting
NCT06815354 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which TRAQinform Theranostics is the first listed.
NCT06815354 reports a single indexed study location in New York, Texas.
Frequently Asked Questions
What is clinical trial NCT06815354 about?
NCT06815354 is a clinical study titled "Comprehensive Assessment of Cancer Theranostic Response". The intent of this study is to evaluate actionable outputs from TRAQinform Theranostics in a prospective, multi-center, non-interventional clinical study. The primary objective is to investigate intent-to-change treatment decisions after the addition of TRAQinform Theranostics. The exploratory objec...
What is the current status of trial NCT06815354?
This trial is currently recruiting. It is a NA study. The enrollment target is 32 participants. The study started on 2024-12-02. Estimated completion is 2026-05-29.
What conditions does trial NCT06815354 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT06815354?
The interventions under investigation include: TRAQinform Theranostics (DEVICE).
Who is sponsoring clinical trial NCT06815354?
This trial is sponsored by AIQ Solutions, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06815354 being conducted?
This trial has 2 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06815354's enrollment target sits among peer trials
32 566th of 735 higher than 159 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI